Related Experiment Videos

Doripenem

David Leif Anderson1

  • 1Medical Information Department, Prous Science, Barcelona, Spain. leifanderson@aol.com

Drugs of Today (Barcelona, Spain : 1998)
|July 18, 2006
PubMed

Insights

Doripenem is a novel carbapenem antibiotic offering broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria. It shows potential advantages over meropenem for specific pathogens, including certain Pseudomonas aeruginosa strains.

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Doripenem is a carbapenem antibiotic, a class of beta-lactam antimicrobials.
  • It exhibits broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic pathogens.
  • Its spectrum is comparable to imipenem and meropenem.

Purpose of the Study:

  • To evaluate the spectrum of activity of doripenem.
  • To compare doripenem's efficacy against key hospital-acquired pathogens, including multidrug-resistant strains.
  • To assess doripenem's potential role in empiric therapy.

Main Methods:

  • Antimicrobial susceptibility testing against a range of clinically relevant pathogens.
  • Comparative analysis of doripenem's in vitro activity against other carbapenems, particularly meropenem.
  • Review of clinical data and guidelines for the use of antipseudomonal carbapenems.

Main Results:

  • Doripenem demonstrates broad-spectrum activity, similar to meropenem.
  • It may possess enhanced activity against certain Pseudomonas aeruginosa strains resistant to other carbapenems.
  • Effective against common hospital pathogens like P. aeruginosa and Burkholderia cepacia.

Conclusions:

  • Doripenem is a valuable parenteral antibiotic for treating infections caused by a wide array of bacteria.
  • Its potential for improved activity against specific resistant pathogens warrants consideration in empiric treatment strategies.
  • Combination therapy may be necessary for infections involving multidrug-resistant Gram-positive pathogens or P. aeruginosa.

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Antibiotic Selection00:57

Antibiotic Selection

Overview
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: